Clinical trials: Hyperlipoproteinemia (a)
Atherosclerosis, Hyperlipidemia
Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab
Aim 1: To determine whether therapy with Alirocumab, compared to pre-treatment, will effectively improve carotid atherosclerotic plaque characteristics by reducing Ktrans and LRNC size.
- Trial name
- NCT02992301
- Testing
- Alirocumab
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Westside Medical Associates of Los Angeles
Hypertension, Hyperlipidemia
Hospital-level Variation in the Management of Blood Pressure and Low-density Lipoprotein in the Outpatient Hypertensives in China-a Cross Sectional Study
To investigate the proportion, medication use and control rate of metabolic abnormalities such as dyslipidemia in outpatients with hypertension in different levels of hospitals in China.
- Trial name
- NCT03862183
- Testing
- continuing medical education program
- Where
- China
- Volunteers
- 21,000 people
- Sponsor
- Huashan Hospital
Dyslipidemia
Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia
The purpose of this study is to evaluate the overall safety of Lapaquistat Acetate, once daily (QD), by itself or in combination with atorvastatin in subjects with primary dyslipidemia.
- Trial name
- NCT00487994
- Testing
- Lapaquistat acetate, Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 2,130 people
- Sponsor
- Takeda
Hypercholesterolemia
Efficacy of Lapaquistat Acetate in Subjects With Hypercholesterolemia
The purpose of this study is to determine the role of time of dosing on the lipid-lowering effects of lapaquistat acetate, once daily (QD) or twice daily (BID), in subjects with hypercholesterolemia.
- Trial name
- NCT00865228
- Testing
- Lapaquistat acetate
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Takeda
Hyperlipidemia
Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
- Trial name
- SPIRE-LL (NCT02100514)
- Testing
- Bococizumab (PF-04950615; RN316)
- Where
- 223 sites in United States, Canada and 10 more
- Volunteers
- 746 people
- Sponsor
- Pfizer
Hypercholesterolemia, Hyperlipoproteinemia
A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin
Lifibrol is a new lipid-lowering drug which lowers cholesterol to an extent in the order of magnitude of the statins. The mechanism of action of this compound is different from the one of statins but remains unknown.
- Trial name
- NCT01057654
- Testing
- Pravastatin, Lifibrol
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bonn
Familial Hypercholesterolemia
Cascade Testing In Identifying At-risk Family Members Of Individuals With Familial Hypercholesterolemia (FH) In PCP
The purpose of this study is to evaluate the effectiveness of two models of cascade testing in identifying at-risk family members of individuals diagnosed with familial hypercholesterolemia (FH).
- Trial name
- NCT07653555
- Testing
- Cascade testing, Standard of Care
- Where
- United States
- Volunteers
- 480 people
- Sponsor
- Mayo Clinic
Hypertension, Hyperlipidemia
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of…
- Trial name
- NCT02569814
- Testing
- Fimasartan/Amlodipine/Rosuvastatin, Fimasartan/Amlodipine, Rosuvastatin
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Elevated Lipoprotein(a) in Hospital Staff
The objective of this study is to investigate the prevalence of elevated Lp(a) in the working general population.
- Conditions
- Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia, Cardiovascular Diseases
- Trial name
- LPACO (NCT06304415)
- Where
- Singapore
- Volunteers
- 2,800 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Hypertension, Arthritis
The Health Access and Recovery Peer Program
Individuals with serious mental illnesses (SMI) face high rates of medical comorbidity as well as challenges in managing these conditions.
- Conditions
- Hypertension, Arthritis, Coronary Artery Disease, Hepatitis
- Trial name
- HARP (NCT01725815)
- Testing
- HARP Intervention
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Emory University
Hypertriglyceridemia, Hyperlipoproteinemia Type IV
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients
The primary purpose of this trial is to determine if the treatment with rosuvastatin 10 and 20mg/day during 8 weeks in hypertriglyceridemic patients will reduce their triglyceride levels.
- Conditions
- Hypertriglyceridemia, Hyperlipoproteinemia Type IV, Hyperlipoproteinemia Type V, Hyperlipoproteinemia Type IIb
- Trial name
- NCT00473655
- Testing
- rosuvastatin
- Where
- 3 sites in Mexico
- Volunteers
- 334 people
- Sponsor
- AstraZeneca
Hyperlipidemia
A Study to Evaluate COR-1004 in Adult Volunteers.
This research study is being done to see if a new, injectable drug called COR-1004 is safe for people to take. It will also help doctors find the right dose of the drug.
- Trial name
- NCT07229118
- Testing
- COR-1004
- Where
- 2 sites in New Zealand
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Corsera Health
Dyslipidemia, Healthy Volunteers
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients
This study will assess the safety, tolerability, and effect of TAP311 on blood lipids in healthy subjects and in patients who have dyslipidemia.
- Trial name
- NCT01487460
- Testing
- TAP311
- Where
- United States
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Hypertension
Effects of Use of a Connected Pillbox On Medication Adherence
Medication adherence is defined as the extent to which a patient takes his or her medication as prescribed by their healthcare provider.
- Conditions
- Diabetes Mellitus, Hypertension, Hyperlipidemia
- Trial name
- (TVHST2DM) (NCT02593032)
- Testing
- Pre-filled trays
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Hyperlipidemia
A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia
This study will be conducted to assess the status of oxidative stress inflammation and thrombogenesis in patients with hyperlipidemia and to compare the antioxidative, anti-inflammatory and antithrombogenic effects of…
- Trial name
- NCT02979704
- Testing
- Rosuvastatin, Atorvastatin
- Where
- Bangladesh
- Volunteers
- 90 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Hyperlipidemia
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00362206
- Testing
- Fenofibrate/Simvastatin, Pravastatin
- Where
- 41 sites in Greece, Israel and 3 more
- Volunteers
- 423 people
- Sponsor
- Solvay Pharmaceuticals
Diabetes Mellitus, Type 2, Hyperlipidemia
A Brief Intervention to Improve Medication Knowledge and Adherence Among Family Medicine Patients in South Texas
This study examines a brief physician counseling intervention to improved medication knowledge and compliance in family medicine patients who have diabetes, hypertension or high cholesterol.
- Conditions
- Diabetes Mellitus, Type 2, Hyperlipidemia, Hypertension
- Trial name
- NCT00846300
- Testing
- Physician counseling for health behavior change
- Where
- 6 sites in United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
- Trial name
- NCT04951219
- Testing
- Resmetirom
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 810 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Hyperlipidemia
Clinical Trial to Evaluate the Efficacy and Safety of CKD-391
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Factorial Design, Phase III Clinical Trial.
- Trial name
- NCT02451098
- Testing
- Atorvastatin10mg, Ezetimibe10mg, Atorvastatin20mg, Ezetimibe10mg, Atorvastatin40mg, Ezetimibe10mg
- Where
- South Korea
- Volunteers
- 385 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hyperlipemia, Carbohydrate Inducible
Milk as a Recovery Beverage After Exercise for Improving Metabolic Health
Fasting blood fat levels (triglycerides) are often used to assess risk of heart disease but the level of fats in the blood after a meal is actually a stronger risk factor.
- Trial name
- NCT03154216
- Testing
- Exercise, Drink
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Saskatchewan